Withings unveiled its latest innovation, the Body Scan 2 smart scale, at CES 2026, positioning it as the 'world's first science-backed longevity station'. This advanced device aims to transform daily weigh-ins into comprehensive health assessments, offering insights into long-term health and the aging process. The Body Scan 2 is designed to measure over 60 biomarkers, providing a more detailed picture of an individual's health than typical smart scales. Key features of the Body Scan 2 include hypertension risk notification, a full assessment of cardiac pumping efficiency via Impedance Cardiography (ICG), and an in-depth evaluation of cellular health, metabolic efficiency, and glycemic regulation through ultra-high-frequency bioimpedance spectroscopy (BIS). It also incorporates a 6-lead ECG and measures arterial stiffness, offering capabilities often found in smartwatches or clinical settings. The device features a retractable handle with a color screen that displays on-the-spot metrics during the 90-second scan. Priced at $599.95 (approximately 499.95€ or £449.95), the Withings Body Scan 2 is slated for release in the second quarter of 2026. However, its launch is pending FDA clearance for several of its advanced metrics. Withings claims the rechargeable battery can last up to 15 months, and all health data automatically syncs to the Withings app via Wi-Fi or Bluetooth. The company emphasizes that the Body Scan 2 is meant for early detection and guidance towards lifestyle changes, rather than providing diagnostic results.